

**Jubilant Life Sciences International Pte. Limited**  
**Balance Sheet as at 31 March 2025**

		USD	INR (In Thousands)	USD	INR (In Thousands)
	Notes	As at 31 March 2025		As at 31 March 2024	
<b>ASSETS</b>					
<b>Non-current assets</b>					
<b>Financial assets</b>					
Investments	1	200,000	17,095	200,000	16,681
Loans and advances	2	19,203,727	1,641,439	19,203,701	1,601,685
<b>Total non-current assets</b>		<b>19,403,727</b>	<b>1,658,534</b>	<b>19,403,701</b>	<b>1,618,366</b>
<b>Current assets</b>					
Cash and cash equivalents	3	1,020,486	87,226	2,356,558	196,549
Other financial assets	4	-	-	137,514	11,469
Income tax asset (net)		4,018	343	-	-
<b>Total current assets</b>		<b>1,024,504</b>	<b>87,569</b>	<b>2,494,072</b>	<b>208,018</b>
<b>Total assets</b>		<b>20,428,231</b>	<b>1,746,103</b>	<b>21,897,773</b>	<b>1,826,384</b>
<b>EQUITY AND LIABILITIES</b>					
<b>Equity</b>					
Equity share capital	5	437,503	19,990	437,503	19,990
Other equity		16,778,748	1,451,569	21,446,988	1,805,286
<b>Total equity</b>		<b>17,216,251</b>	<b>1,471,559</b>	<b>21,884,491</b>	<b>1,825,276</b>
<b>LIABILITIES</b>					
<b>Current liabilities</b>					
<b>Financial liabilities</b>					
Trade payables	6	11,196	957	7,394	617
Provisions for dividends		3,200,000	273,520	-	-
Current tax liabilities	7	784	67	5,888	491
<b>Total current liabilities</b>		<b>3,211,980</b>	<b>274,544</b>	<b>13,282</b>	<b>1,108</b>
<b>Total liabilities</b>		<b>3,211,980</b>	<b>274,544</b>	<b>13,282</b>	<b>1,108</b>
<b>Total equity and liabilities</b>		<b>20,428,231</b>	<b>1,746,103</b>	<b>21,897,773</b>	<b>1,826,384</b>

SS Hariharasubramaniam  
Sr. Director – Accounts  
Place: Noida  
Date: 12 May 2025

**Jubilant Life Sciences International Pte. Limited**  
**Statement of Profit and Loss for the year ended 31 March 2025**

Particulars	Notes	USD	INR (In Thousands)	USD	INR (In Thousands)
		For the year ended 31 March 2025		For the year ended 31 March 2024	
Other income	8	823,189	69,540	782,197	64,744
<b>Total income</b>		<b>823,189</b>	<b>69,540</b>	<b>782,197</b>	<b>64,744</b>
<b>Expenses</b>					
Other expenses	9	162,152	13,983	24,484	2,026
<b>Total expenses</b>		<b>162,152</b>	<b>13,983</b>	<b>24,484</b>	<b>2,026</b>
<b>Profit before tax</b>		<b>661,037</b>	<b>55,557</b>	<b>757,713</b>	<b>62,718</b>
Tax expense					
- Current tax		29,277	2,558	40,837	3,391
<b>Total tax expense</b>		<b>29,277</b>	<b>2,558</b>	<b>40,837</b>	<b>3,391</b>
<b>Profit after tax</b>		<b>631,760</b>	<b>52,999</b>	<b>716,876</b>	<b>59,327</b>
<b>Other comprehensive income</b>					
<i>Items that will not be reclassified to profit or loss</i>					
Exchange differences on translation of foreign operations		-	51,930	-	26,606
Other comprehensive income/(loss) for the year, net of tax		-	51,930	-	26,606
<b>Total comprehensive income/(loss) for the year</b>		<b>631,760</b>	<b>104,929</b>	<b>716,876</b>	<b>85,933</b>

SS Hariharasubramaniam  
Sr. Director – Accounts  
Place: Noida  
Date: 12 May 2025

**Jubilant Life Sciences International Pte. Limited**  
**Statement of changes in Equity for the year ended 31st March 2025**

**A. Equity share capital**

	USD	INR (In Thousands)
<b>Balance as at 1 April 2023</b>	437,503	19,990
Changes in equity share capital during the year	-	-
<b>Balance as at 31 March 2024</b>	437,503	19,990
Changes in equity share capital during the year	-	-
<b>Balance as at 31 March 2025</b>	437,503	19,990

**B. Other equity**

	Reserves and surplus					Total	
	Retained earnings		Capital Reserve		Exchange differences on translation of foreign operations		
	USD	INR (In Thousands)	USD	INR (In Thousands)	INR (In Thousands)	USD	INR (In Thousands)
<b>Balance as at 1 April 2023</b>	13,672,442	997,696	7,057,670	473,429	248,228	20,730,112	1,719,353
Profit for the year	716,876	59,327	-	-	-	716,876	59,327
Exchange differences on translation of foreign operations	-	-	-	-	26,606	-	26,606
<b>Balance as at 31 March 2024</b>	14,389,318	1,057,023	7,057,670	473,429	274,834	21,446,988	1,805,286
<b>Balance as at 1 April 2024</b>	14,389,318	1,057,023	7,057,670	473,429	274,834	21,446,988	1,805,286
Profit for the year	631,760	52,999	-	-	-	631,760	52,999
Exchange differences on translation of foreign operations	-	-	-	-	51,930	-	51,930
<b>Total comprehensive income for the year</b>	15,021,078	1,110,022	7,057,670	473,429	326,764	22,078,748	1,910,215
<b>Transaction with owners in their capacity as owners:</b>							
Dividends	(5,300,000)	(458,646)	-	-	-	(5,300,000)	(458,646)
<b>Balance as at 31 March 2025</b>	9,721,078	651,376	7,057,670	473,429	326,764	16,778,748	1,451,569

SS Hariharasubramaniam  
Sr. Director – Accounts  
Place: Noida  
Date: 12 May 2025

**Jubilant Life Sciences International Pte. Limited**  
**Statement of Cash Flows for the year ended 31 March 2025**

Particulars	USD	INR (In Thousands)	USD	INR (In Thousands)
	For the year ended 31 March 2025		For the year ended 31 March 2024	
<b>A. Cash flow from operating activities</b>				
Net profit before tax	661,037	55,557	757,713	62,718
Adjustments :				
Interest Income	(823,189)	(69,540)	(782,197)	(64,744)
Irrecoverable balances written off	137,514	11,900	-	-
<b>Operating cash flow before working capital changes</b>	<b>(24,638)</b>	<b>(2,083)</b>	<b>(24,484)</b>	<b>(2,026)</b>
(Increase)/ decrease in other current assets and loan and advances	(26)	(2)	60	5
Increase/ (decrease) in trade payables and current liabilities	3,803	321	(490)	(41)
<b>Cash used in operations</b>	<b>(20,861)</b>	<b>(1,764)</b>	<b>(24,914)</b>	<b>(2,062)</b>
Income tax paid (net of refund)	(38,400)	(3,245)	(40,360)	(3,340)
<b>Net cash (used) in operating activities</b>	<b>(59,261)</b>	<b>(5,009)</b>	<b>(65,274)</b>	<b>(5,402)</b>
<b>B. Cash flow from investing activities</b>				
Interest Received	823,189	69,540	782,197	64,744
Dividend paid	(2,100,000)	(177,302)	-	-
Loan given to related parties	-	-	-	-
<b>Net cash (used)/ generated from investing activities</b>	<b>(1,276,811)</b>	<b>(107,762)</b>	<b>782,197</b>	<b>64,744</b>
<b>C. Effect of exchange rate changes</b>	-	3,448	-	2,478
<b>Net (decrease)/ increase in cash and cash equivalents (A+B+C)</b>	<b>(1,336,072)</b>	<b>(109,323)</b>	<b>716,923</b>	<b>61,820</b>
Add: cash and cash equivalents at the beginning of year	<b>2,356,558</b>	<b>196,549</b>	<b>1,639,635</b>	<b>134,729</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>1,020,486</b>	<b>87,226</b>	<b>2,356,558</b>	<b>196,549</b>

SS Hariharasubramaniam

Sr. Director – Accounts

Place: Noida

Date: 12 May 2025

**Jubilant Life Sciences International Pte. Limited**  
**Notes to the financial statements for the year ended 31 March 2025**

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2025		As at 31 March 2024	
<b>Note 1. Non-current investments</b>				
<b>Investment in subsidiaries</b>				
Investment in Jubilant Life Sciences (Shanghai) Limited 200,000 (31 March 2024:200,000 equity share of USD 1 each)	200,000	17,095	200,000	16,681
	<b>200,000</b>	<b>17,095</b>	<b>200,000</b>	<b>16,681</b>
<b>Note 2. Long term loan and advances</b>				
Security deposits	3,727	319	3,701	309
Loans to related parties	19,200,000	1,641,120	19,200,000	1,601,376
	<b>19,203,727</b>	<b>1,641,439</b>	<b>19,203,701</b>	<b>1,601,685</b>
<b>Note 3. Cash and cash equivalent</b>				
<b>Balances with banks:</b>				
- On current accounts	73,427	6,276	892,361	74,427
- On deposit accounts	947,059	80,950	1,464,197	122,122
	<b>1,020,486</b>	<b>87,226</b>	<b>2,356,558</b>	<b>196,549</b>
<b>Note 4. Other financial assets</b>				
Advance recoverable-related party	-	-	137,514	11,469
	<b>-</b>	<b>-</b>	<b>137,514</b>	<b>11,469</b>

**Jubilant Life Sciences International Pte. Limited**  
**Statement of changes in Equity for the year ended 31st March 2025**

**Note 5: Equity share capital**

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2025		As at 31 March 2024	
<b>Issued, subscribed and paid up share capital</b>				
437,503 (31 March 2024: 437,503 Equity shares with no par value)	437,503	19,990	437,503	19,990
	<b>437,503</b>	<b>19,990</b>	<b>437,503</b>	<b>19,990</b>

**1). Movement in Equity share capital**

	No. of shares	USD	INR (In Thousands)
<b>Balance as at 1 April 2023</b>	437,503	<b>437,503</b>	<b>19,990</b>
Changes in equity share capital during the year	-	-	-
<b>Balance as at 31 March 2024</b>	437,503	<b>437,503</b>	<b>19,990</b>
Changes in equity share capital during the year	-	-	-
<b>Balance as at 31 March 2025</b>	437,503	<b>437,503</b>	<b>19,990</b>

**2) Terms and rights attached to equity shares**

The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

**3) The details of shareholders holding more than 5% shares in the company**

	As at 31 March 2025		As at 31 March 2024	
Name of the Shareholder	No. of shares	% holding in the class	No. of shares	% holding in the class
Jubilant Ingrevia Limited	437,503	100%	437,503	100%

**Jubilant Life Sciences International Pte. Limited****Notes to the financial statements for the year ended 31 March 2025**

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2025		As at 31 March 2024	
<b>Note 6. Trade payables</b>				
Trade payables	11,196	957	7,394	617
	<b>11,196</b>	<b>957</b>	<b>7,394</b>	<b>617</b>
<b>Note 7. Current tax liabilities</b>				
Provision for income tax	784	67	5,888	491
	<b>784</b>	<b>67</b>	<b>5,888</b>	<b>491</b>
	<b>For the year ended 31 March 2025</b>		<b>For the year ended 31 March 2024</b>	
<b>Note 8. Other income</b>				
Interest Income	823,189	69,540	782,197	64,744
	<b>823,189</b>	<b>69,540</b>	<b>782,197</b>	<b>64,744</b>
<b>Note 9. Other expenses</b>				
Auditors remuneration	9,422	798	6,696	554
Legal, professional and consultancy charges	14,773	1,247	17,086	1,414
Bank charges	469	40	643	53
Irrecoverable advances	137,514	11,900	-	-
Foreign exchange (gain)/ loss	(26)	(2)	59	5
	<b>162,152</b>	<b>13,983</b>	<b>24,484</b>	<b>2,026</b>